Andrew is a Director at a venture capital firm, Midven. As Fund Principal of the UK Innovation & Science Seed Fund and the Early Advantage Fund, Andrew led two rounds of investment into Atelerix.
Andrew’s background in sciences started with a degree and a PhD in Chemistry from the University of Oxford. After an initial scientific career at Zeneca, he went on to roles in research and business development at the medical device company Biocompatibles, and then Vice President of Technology for a US start-up in disinfection of medical equipment.
He started his career in venture capital with the £4m per annum Invention and Innovation seed capital fund at NESTA (the National Endowment for Science Technology and the Arts).
Andrew combines a strong scientific and technical grounding with a real commercial pragmatism developed from his operational roles.